If tumor burden is high, high-dose RT helps to ‘prime’ T cells at primary tumor site, low-dose RT ‘modulates the stroma’ at secondary metastatic site. Low-dose RT can improve the outcomes of ICI by promoting M1 macrophage polarization, enhancing NK cell infiltration, and reducing TGF-β. This evidence concerns the gene TGFB1 and neoplasm.